Specimen Reference Sets
Organ | Protocol ID | Reference Set Title | Cases | Controls | Total Participants | Participant groups | Specimen type | Number of specimens | Volume range, mL | Specimens at NCI-F? | Sequential samples? | Follow-up data? | Pathology? | Image files available? | Incidental cancer? | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast | 331 | Benign Breast Disease | 30 | 62 | 92 | BBD that progressed to cancer BBD controls |
Tissue slides | 9,256 | "each" | No, at Kansas | N/A | No | Yes | No | Yes | |
Breast | 121 | Breast | 262 | 570 | 832 | Pre-diagnosis specimens DCIS cases Invasive cancer cases LCIS cases Benign→later cancer cases Normal→later cancer cases Benign Disease Atypia controls Benign Disease non-Atypia controls Normal controls |
Serum | 16,444 | 0.01-0.8 | Yes | No | No | Yes | No | Yes | |
Plasma | 16,169 | 0.01-0.9 | ||||||||||||||
Ovarian & Breast | 118 | Cancers in women-BRSCW | 441 | 95 | 536 | Cases (pooled) Controls (pooled) |
Serum | 105 sets | 0.3 | Yes | No | No | No | No | No | |
Colon | 251 | Colon cancer | 50 | 100 | 150 | Serum | 2,100 | 0.3 | Yes | No | No | No | No | No | ||
Plasma | 1,500 | 0.3 | ||||||||||||||
Urine | 150 | 5 | ||||||||||||||
Liver | 111 | DCP/Liver Ref set Rapid set | 50 | 50 | 100 | Serum | 1,329 | 0.01-0.5 | Yes | No | No | No | No | Yes | ||
Plasma | 731 | 0.2-0.5 | ||||||||||||||
Liver | 111 | DCP/Liver Ref set Validation set | 427 | 432 | 871 | Serum | 10,815 | 0.01-1.0 | Yes | No | No | No | No | No | ||
Plasma | 5,090 | 0.2-0.5 | ||||||||||||||
Lung | 115 | Lung Ref Set A Phase II Validation (retrospective) | 268 | 309 | 577 | Serum | 3,695 | 0.025-0.5 | Yes | No | No | No | No | No | ||
Plasma | 5,267 | 0.15-0.3 | ||||||||||||||
Lung | 115 | Lung Ref Set B (retrospective) | 86 | 147 | 233 | Plasma | 3,846 | 0.025-0.375 | Yes | No | No | No | No | No | ||
Lung | 115 | Lung Ref Set C (prospective) | 159 | 195 | 354 | Serum | 6,430 | 0.015-0.2 | Yes | No | No | No | No | No | ||
Plasma | 6,787 | 0.01-0.175 | ||||||||||||||
Pancreas | 185 | Pancreatic cancer | 100 | 155 | 255 | Serum | 4,847 | 0.1-0.8 | Yes | No | No | Yes | No | No | ||
Plasma | 3,006 | 0.2-0.8 | ||||||||||||||
Prostate | 274 | Prostate cancer (from PCA3) | 341 | 559 | 900 | Serum | 16,778 | 0.075-0.5 | Yes | No | No | No | No | Yes | ||
Bufy coat | 864 | 0.05-0.5 | ||||||||||||||
Whole urine | 771 | 1.2-5.0 | ||||||||||||||
EDTA plasma | 13,137 | 0.1 | ||||||||||||||
Sediment/RNALater | 738 | 0.035-1.5 | ||||||||||||||
Sediment/PBS | 486 | 0.01-0.4 | ||||||||||||||
Supernatant | 1,493 | 2.5-50 | ||||||||||||||
PAXGene | 1,716 | "tubes" | ||||||||||||||
Pancreas | 342 | Panc Cyst | 48 | 270 | 318 | Serum | 16,958 | 0.1-0.3 | Yes | No | No | No | No | Yes | ||
EDTA plasma | 8,605 | 0.1-0.3 | ||||||||||||||
EUS Cystic Fluid | 5,538 | 0.05-0.1 | ||||||||||||||
Surgical Cystic Fluid | 4,599 | 0.1-0.6 | ||||||||||||||
General Documents for Reference Sets
- EDRN Guidelines
- Application Form for EDRN Reference Sets
Ovarian & Breast Cancer Reference Sets
- Biomarker Reference Sets for Cancers in Women (BRSCW) (PDF)
- Description of pooled reference sets for ovarian and breast cancer serum specimens
- BRSCW Application Form
Breast Cancer Reference Sets
- Breast Reference Set Summary (PDF)
- Breast Reference Set Protocol (PDF)
- Breast Reference Set Participant and Clinical Forms (PDF)
- Application Form for EDRN Reference Sets
EDRN Benign Breast Disease Tissue Resource (BBD)
- BBD Reference Set Summary Document (PDF)
Benign Breast Disease Application (PDF) - SOP For Selection of Benign Breast Disease Project
Lung Cancer Reference Sets
- Lung Cancer Reference Set Documentation (PDF)
- The goal of the NCI/EDRN/SPORE Lung Cancer Biomarkers Group (LCBG) is to develop the requisite sample resources to pre-validate serum/plasma biomarkers for the early diagnosis of lung cancer.
-
- Application Form for EDRN Reference Sets
Colon Cancer Reference Set
- Colon Cancer Reference Set Description (PDF)
-
- Application Form for EDRN Reference Sets
Prostate Cancer Reference Sets
- Prostate Cancer Reference Set Description (PDF)
- One of the goals of the EDRN Genitourinary (GU) Collaborative Group is the establishment of a biologic sample set on men prior to prostate biopsy, in association with clinical information and common data elements appropriate for evaluation of risk and prognosis of prostate cancer.
-
- Application Form for EDRN Reference Sets
-
PCA3 Validation Study and Urinary Reference Set
Liver (Hepatocellular Carcinoma) Reference Set
Hepatocellular Carcinoma Reference Set Description (PDF)
- Application Form for EDRN Reference Sets
Pancreatic Standard Specimen Reference Set
-
- Pancreatic Cancer Reference Set Access Information (PDF)
-
- Application Form for EDRN Reference Sets
-
-